PositiveID's Implantable Microchips

PositiveID Corporation Reaches Important Chemistry Milestone in Development of Its Implantable Glucose-sensing Microchip

Company Expects to Complete Sensing System Development by Mid-Year

March 2, 2011

GLOBE NEWSWIRE - PositiveID Corporation (Nasdaq:PSID) announced today that it has reached an important chemistry milestone in the development of its GlucoChip™, glucose-sensing RFID microchip.

The Company has successfully shown that it is able to construct both anchor and reverse anchor building blocks and competitor constructs, which are able to bind with glucose, that can be incorporated into the sensor. These building blocks and competitor constructs bind with glucose to produce a direct, reproducible correlation of glucose levels.

The Company expects to complete optimization of the sensing system by mid-2011, at which point it will begin to incorporate the glucose sensing system with the electronics of the RFID microchip to complete development of the glucose sensor.

The Company is currently in Phase II development of GlucoChip. As previously announced, the goal of Phase II is to optimize the sensing system for its glucose response and demonstrate the integration of the components into a stable and reproducible glucose sensing system that will be the critical component of the glucose sensor. In Phase II, PositiveID has screened anchor and reverse anchor constructs for their binding with glucose and appropriateness for immobilization on a solid surface. The results of these screenings will be used to select the best sugar binding partner pairs for incorporation into the prototype.

Robert E. Carlson, Ph.D., President and Chief Science Officer at Receptors, PositiveID's development partner, said,

"The significance of today's announcement is that we have reached a point in our development that gives us more confidence that we can create a stable and reproducible glucose sensing system. Constructing a material that binds to glucose and produces a consistent response curve that can be read and correlated to glucose levels was a significant hurdle."

Scott R. Silverman, Chairman and CEO of PositiveID, said,

"We are now at a stage in our development that, we believe, tells us that the chemistry required for GlucoChip supports accurate measurement of glucose, and by mid-year, we anticipate completing the optimization of the glucose sensing system. As we push forward, we are hopeful that we can take GlucoChip to the next stage of development and leverage our expertise with RFID implantable microchips."

GlucoChip is an implantable glucose-sensing microchip currently under development with chemistry partner Receptors LLC. GlucoChip is based on the Company's FDA approved microchip for patient identification, the VeriChip, and the Company's Patent No. 7,125,382 for an "Embedded Bio-Sensor System."

The Company's Embedded Bio-Sensor System patent covers a bio-sensor system that utilizes radio frequency identification technology and includes a remote transponder in wireless communication with an implantable passively-powered on-chip transponder.

PositiveID Corporation Partners With Wireless Technology Leaders at Connected

iglucose Product to be Completed in March 2011 and Submitted to FDA for 510(k) Clearance Shortly Thereafter

February 15, 2011

GLOBE NEWSWIRE - PositiveID Corporation (Nasdaq:PSID), a leader in next generation patient monitoring and diagnostics, announced today it has partnered with Connected Development to complete the final stage of development of its iglucose™ product.

PositiveID's iglucose is a wireless communication device for the automatic transmission of blood glucose readings from any data-capable glucometer to the iglucose database. It functions without the use of a cellular telephone, telephone line or personal computer. PositiveID expects to complete the design and development of the iglucose product in March 2011, and submit it to the U.S. Food and Drug Administration for 510(k) clearance shortly thereafter.

Connected Development is finalizing the product design and embedded software development; validating its performance; managing network certification, and coordinating the manufacturing process for iglucose.

"We are excited to be involved in the development of the iglucose device," said Stefan Lindvall, President of Connected Development. "And, we are confident we can make the ease and convenience of iglucose a reality soon, in order to enhance the quality of life for those living with diabetes."

PositiveID has also finalized the back-end software architecture for iglucose, which is based on Web 2.0 methodologies and facilitates an intuitive user interface, and user-centric design of the application. The iglucose platform, in its final stages, will provide an open-standards API, which will allow data from iglucose to easily integrate with other systems.

PositiveID's iglucose is designed to take the work out of diabetes management by automatically creating logs and journals, which, according to the American Diabetes Association, are an important assessment of an individual's response to their diabetes care plan. Users simply connect their data-capable glucometer to iglucose and within seconds data will be transmitted via a machine-to-machine (M2M) network to the iglucose database. PositiveID believes the solution is ideal for individuals, healthcare providers, health insurers, wellness and disease management companies who are actively seeking solutions to reduce diabetes related costs.

"As we complete the final stage of development and validation of iglucose, we have chosen another expert in wireless communication and M2M technology to prepare us for our FDA submission," said Scott R. Silverman, Chairman and CEO of PositiveID. "We are confident working with Connected Development will help us bring our solution to market quickly and effectively."

PositiveID Corporation Completes Development of Temperature-Sensing Microchip

Microchip Will Integrate With PositiveID's Wireless Body(TM) Platform to Provide Early Warning at the Onset of an Illness

January 18, 2011

GLOBE NEWSWIRE - PositiveID Corporation (Nasdaq:PSID) announced today that it has completed the development of its temperature-sensing microchip in conjunction with development partner RFID Solutions of Malaga, Spain.

The microchip, which uses radio frequency identification (RFID) technology, is able to measure internal temperature within the body and communicate that temperature wirelessly to an external reader. The Company plans to integrate the temperature-sensing microchip with its Wireless Body™ platform.

As previously announced in November 2010, PositiveID teamed up with RFID Solutions, an advanced technical development group with innovative automated manufacturing and expertise in specialized requirements for sensors in RFID markets, to develop the temperature-sensing microchip for use in humans.

The Company expects its Wireless Body platform will continue to evolve with the addition of other bio-sensing capabilities, including glucose-sensing through its GlucoChip™, which is currently under development. The Wireless Body will be designed to enhance wellness and disease management, for diabetes and other chronic illnesses, by allowing healthcare systems to communicate with each other and deliver solutions to patients seamlessly.

Scott R. Silverman, Chairman and CEO of PositiveID, said,

"When a person spikes a fever, it is a signal that their body is fighting an infection. By being able to continuously monitor temperature, it could provide an early warning to a caregiver at the onset of an illness. With the completion of this first bio-sensing microchip we will also explore other bio-sensing functions to integrate with the Wireless Body through our patent for an embedded bio-sensor system to improve remote patient monitoring."

The Wireless Body communication system is built on the Company's Patent No. 7,125,382 for an Embedded Bio-Sensor System.

Read More...